


Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 07180/004003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Serial No.	09/827,854	
				Applicant	Vassilis I. Zannis et al.	
				Filing Date	April 5, 2001	
				Group	1636	
				IDS Filed	January 20, 2004	
				Customer No.	21559	
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
QN	Chen et al., "Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low density lipoprotein receptor," <i>Molecular Therapy</i> 2:256-261 (2000).					
QN	Gerritsen et al., "Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain," <i>J. Lipid Research</i> 44:408-414 (2003).					
QN	Oka et al., "Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor," <i>Circulation</i> 103:1274-1281 (2001).					
EXAMINER				DATE CONSIDERED	4/12/04	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						